Current treatment for celiac disease

The only known treatment for celiac disease at this time is a strict gluten-free diet for life. There are no drugs or over-the-counter remedies on the market to prevent or treat celiac disease, or to prevent symptoms or longterm health consequences of gluten exposure.

Future treatment:

Research is under way by the following companies and institutions to find pharmaceutical or alternative treatments. Some of them are in clinical trial, ranging from early to late stage development.

List updated March 2017

Amyra Biotech, Switzerland (developing gluten-targeting enzymes)

Avaxia Biologics, Massachusetts (identifying potential inflammatory cytokine targets for gut-targeted antibodies that may ameliorate the disease)

BioLineRX, Israel (developing BL-7010, a polymer that sequesters gliadins, masking them from enzymatic degradation and preventing the formation of immunogenic peptides, reducing the immune response)

Calypso Biotech, Switzerland (developing CALY-002, a humanized monoclonal antibody inhibiting Interleukin-15 (IL-15), as a treatment for refractory celiac disease)

Celimmune, New Jersey / Amgen, California (developing anti-IL-15 monoclonal antibody AMG 714 as a treatment for nonresponsive and refractory celiac disease)

Cour Pharma/ Takeda, Japan (developing nanotechnologies, called Tolerizing Immune Modifying nanoParticle (TIMP) platform, that inhibit the immune responses)

ExPharma Limited/Nemysis Limited UK/ Ireland (developing portfolio of IP protected, science-based compounds and products to be brought to market as prescription Medical Foods, for the management of triggers and symptoms)

Dr. Falk, Germany / Zedira, Germany (developing ZED1227, direct acting inhibitor of tissue transglutaminase)

enGene, Inc, Canada (developing nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues)

Glenmark Pharmaceuticals Ltd., India (developing monoclonal antibody GBR 830)

ImmunogenX, California/ Alvine Pharmaceuticals, California (developing IMGX003, formerly Alvine Pharmaceuticals ALV003)

ImmusanT, Massachusetts (developing Nexvax2)

Innovate Biopharmaceuticals, North Carolina/  Alba Therapeutics, Maryland (developing INN-202, formerly Alba Therapeutics Larazotide Acetate)

Intrexon Corporation, Maryland (developing ActoBiotics)

James Cook University, Australia (studying how hookworm larvae suppress the inflammatory response in celiac patients)

Kanyos Bio, Massachusetts/ Anokian, Switzerland/ Astellas, Japan  (developing engineered proteins to inhibit only the immune cells inducing damage to the intestine)

Provid Pharmaceuticals, New Jersey (developing inhibitors of DQ2 and DQ8, genes associated with celiac disease)

PVP Biologics Washington (developing KumaMax, formerly at University of Washington Institute for Protein Design)

Selecta Biosciences,Massachusetts/  Sanofi, France  (developing Synthetic Vaccine Particles (SVP) technology designed to program the immune system to elicit tolerance to a specific antigen without impacting the rest of the immune system)

Sitari, California (developing targeted inhibitors of Transglutaminase 2 (TG2))

University of Alberta/ TEC Edmonton/ IGY Life Sciences/ Vetanda Group, Canada and UK (developing supplement from the yolks of chicken eggs that prevents the absorption of gliadin)

VU University Medical Centre, Netherlands (developing Aspergillus niger prolyl endoprotease, known as AN-PEP)

The National Institutes of Health has a complete listing of current and completed studies on celiac disease treatments.